Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711693 | 0.81 | ALDH1A1 (1.00) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL2959641 | 0.81 | ALDH1A1 (1.00) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL31036011 | 0.79 | TDP1 (0.56) | MEN1KMT2ACYP1B1MAPTHSD17B10 | |
| SCHEMBL29263664 | 0.79 | TDP1 (0.56) | MEN1KMT2ACYP1B1MAPTHSD17B10 | |
| SCHEMBL245402 | 0.77 | MEN1 (0.68) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL6165776 | 0.75 | CASP3 (0.62) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL29411233 | 0.74 | MEN1 (0.55) | MEN1KMT2AALDH1A1PKMMAPT | |
| SCHEMBL798047 | 0.74 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL17979341 | 0.74 | MEN1 (0.55) | MEN1KMT2AALDH1A1PKMMAPT | |
| SCHEMBL22290229 | 0.73 | MEN1 (0.47) | MEN1KMT2AALDH1A1PKMCYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MEN1 4841/4885KMT2A 773/4885ALDH1A1 433/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MEN1 4876/4885KMT2A 2098/4885ALDH1A1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.